These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1271 related articles for article (PubMed ID: 27565919)
1. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Shien K; Papadimitrakopoulou VA; Wistuba II Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919 [TBL] [Abstract][Full Text] [Related]
2. Durvalumab in non-small-cell lung cancer patients: current developments. Mezquita L; Planchard D Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296 [TBL] [Abstract][Full Text] [Related]
4. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis. Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822 [TBL] [Abstract][Full Text] [Related]
5. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240 [TBL] [Abstract][Full Text] [Related]
7. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. Jiang Y; Zhan H Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776 [TBL] [Abstract][Full Text] [Related]
8. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer. Zhang S; Bai X; Shan F Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710 [TBL] [Abstract][Full Text] [Related]
9. [Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer]. Wu S; Hu C; Wu F; Wu Y; Liu P Zhongguo Fei Ai Za Zhi; 2019 Jul; 22(7):440-448. PubMed ID: 31315783 [TBL] [Abstract][Full Text] [Related]
10. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898 [TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Prelaj A; Tay R; Ferrara R; Chaput N; Besse B; Califano R Eur J Cancer; 2019 Jan; 106():144-159. PubMed ID: 30528799 [TBL] [Abstract][Full Text] [Related]
12. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326 [TBL] [Abstract][Full Text] [Related]
13. Role of immune-checkpoint inhibitors in lung cancer. Jain P; Jain C; Velcheti V Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894 [TBL] [Abstract][Full Text] [Related]
14. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442 [TBL] [Abstract][Full Text] [Related]
15. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694 [TBL] [Abstract][Full Text] [Related]
16. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694 [TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242 [TBL] [Abstract][Full Text] [Related]
18. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652 [TBL] [Abstract][Full Text] [Related]
19. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391 [TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Hsu PC; Jablons DM; Yang CT; You L Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]